Phase I Study of HC-7366 for Acute Myeloid Leukemia
To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.
Trial Details
- NCT ID
- NCT06285890
- Phase
- PHASE1
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Patients need to have a confirmed diagnosis of AML, or MDS/AML with 10% to 19% blasts, per the International Consensus Classification 2022 or the W…
- Dose escalation phase
- Patients ≥18 years with R/R AML or R/R MDS/AML, other than acute promyelocytic leukemia (APL), with no available standard treatment options.
- Relapsed or refractory disease defined by standard criteria as follows:
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →